Health Care Technology
Company Overview of GNS Healthcare, Inc.
GNS Healthcare, Inc. provides analytics solutions for the healthcare industry. It offers Reverse Engineering and Forward Simulation Technology, a supercomputer-enabled framework that automates the extraction of causal network models directly from observational data and uses high-throughput simulations to generate new knowledge. The company also provides real-world outcomes solutions for data that comes from electronic health records, claims, clinical programs, and incentive and reward programs; product development solutions for biopharmaceutical, diagnostic, consumer product, and medical device companies; and publications, conference abstracts, and presentations. It serves pharmaceutical and...
One Charles Park
Cambridge, MA 02142-1254
Founded in 2000
Key Executives for GNS Healthcare, Inc.
Co-Founder, Chairman of the Board, Chief Executive Officer and President
Co-Founder and Executive Vice President
Chief Mathematics Officer
Compensation as of Fiscal Year 2014.
GNS Healthcare, Inc. Key Developments
GNS Healthcare Appoints Tom McNamara as Chief Revenue Officer
Mar 31 15
GNS Healthcare announced that Tom McNamara has joined the company as Chief Revenue Officer. In this role, McNamara will shape the GNS sales organization to serve an expanding roster of clients, including health plans, healthcare providers, biopharmaceutical companies, foundations, and others. Most recently McNamara served as Senior Vice President and Chief Revenue Officer for HighRoads.
The Multiple Myeloma Research Foundation and GNS Healthcare Announce Collaboration to Identify Potential New Multiple Myeloma Therapies
Jan 7 15
GNS Healthcare announced a collaboration to speed the discovery of innovative treatments for patients with multiple myeloma. The effort will combine the unprecedented genomic and clinical data from the MMRF's CoMMpass Study with revolutionary GNS machine learning platforms and rapid computer simulations. The work supports the development of computer models of myeloma disease that may uncover novel molecular pathways that can prevent progression of disease and address the unmet treatment needs of patients with multiple myeloma. CoMMpass is a longitudinal study of 1,000 newly diagnosed patients with active multiple myeloma. Its objective is to map each of these patients genomic profiles to clinical outcomes to develop a more complete understanding of patient responses to treatments. GNS will use an in silico process, applying its MAX architecture and patented REFS inference engine and simulation platforms to the CoMMpass data. REFS will identify causal drivers and underlying molecular processes of disease progression. REFS will also discover the most likely targets for therapeutics to treat, and perhaps to predict and prevent, relapses and refractory disease. REFS will also discover predictive diagnostic biomarkers that determine which treatments will work and for which patients. The work promises to support physicians and patients with a broader set of individualized treatment protocols mapped to specific molecular and genomic characteristics. GNS has used REFS successfully to advance the research priorities of numerous nonprofit organizations focused on diseases including Huntington’s disease, multiple sclerosis, childhood asthma, Alzheimer's disease and others. Its work ultimately enables next-generation care management solutions focused on reducing adverse events, slowing disease progression and improving therapeutic effectiveness through precision medicine.
GNS Healthcare Announces Executive Appointments
Dec 17 14
GNS Healthcare announced the addition of Richard Popiel, MD, MBA and Atul Butte, MD, PhD to its Scientific Advisory Board. Dr. Popiel is executive vice president of health care services and chief medical officer at Cambia Health Solutions. Widely regarded as a population health expert, Dr. Popiel previously served Horizon Blue Cross Blue Shield of New Jersey as president and chief operating officer and as vice president and chief medical officer. His work has focused on personalizing care and on implementing innovative models of care that improve patient outcomes while containing costs. Dr. Butte is chief and associate professor, division of systems medicine, departments of pediatrics and genetics, Stanford University and the Lucile Packard Children's Hospital. The Butte Laboratory builds and applies tools that convert more than 400 trillion points of molecular, clinical, and epidemiological data measured by researchers and clinicians over the past decade into diagnostics, therapeutics, and new insights into disease.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 19, 2015